Sorafenib for Cancer Research Stay Continued
Cancer November 2nd, 2009
Bayer Schering Pharma to continue research and testing of the use of sorafenib in the treatment of some types of cancer, other than liver cancer and kidney cancer. The study included the use of sorafenib efficacy in cases of lung cancer, breast cancer, skin cancer, thyroid cancer, and leukemia.
Further research be conducted after the effective sorafenib can inhibit the growth and spread of cancer cells in cases of liver cancer and kidney cancer. Bayer Schering Pharma to invest 400 million U.S. dollars to help the researchers to the program.
It was mentioned by Dr Dimitris Voliotis, Vice President of Global Clinical Development Montville Bayer Healthcare, the U.S., in a media workshop in Taipei, Taiwan, Sunday (27 / 9). “Sorafenib is clinically proven to be able to suppress the growth and spread of cancer cells in cases of liver and kidney cancer. So there is hope, sorafenib effectively to suppress the growth and spread of cancer cells in other cancers. That’s what we’re careful with approximately 200 researchers from around the world, “said Voliotis.
Research carried out by using the production of sorafenib tablets, Bayer trademark Nexavar, the only tablet that has received sorafenib use in various countries. The results obtained are expected to begin in 2010. “One of the expected result is known to phase III efficacy study for the case of sorafenib lung non-small cell carcinoma (nonsmall cell lung cancer / NSCLC),” said Voliotis.
Advanced
Director of the Barcelona Clinic Cancer Group Lever Professor Jordi Bruix states, a new liver cancer are generally handled at an advanced stage, then discard operation or transplantation of cancer cells can not be done. One reason is because the symptoms are too general. In some cases, people with no symptoms of liver cancer to advanced stage.
“Sorafenib shown to inhibit and even reduce, the growth and spread of liver cancer cells so that the patient’s life expectancy increases. And sorafenib is safe for use in the long term. In Spain even be obtained free of charge because the government paid for, “said Bruix.
Consular gastroenterohepatologi Cancer Hospital Darmais Jakarta, Dr. Agus Sudiro SpPD KGEH, explained, since 2007 sorafenib has become an alternative treatment of liver cancer patients in Indonesia.
“In some cases there is success. The price is very expensive. For a month, to Rp 60 million. Because there is assistance from drug manufacturers, patient enough to buy medicines for the first three months, after it was free, “said Agus.
